Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.800.17%
QQQ
718.750.33%
BTC/USD
79842.940.5313%
DIA
534.730.09%
GLD
421.170.34%
TLT
83.090.05%

DiaMedica Therapeutics Inc

DMACNASDAQ
Trade with Public
Trade with Public
$6.75
0.050.75%
At close: Aug 27, 5:00 PM EST
$6.75
N/A
After Hours: 4:00 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

DiaMedica Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for DiaMedica Therapeutics (DMAC).

Price Target Range — 9 Quarters

Analyst Consensus — 5 Analysts

5Buy
Consensus RatingBuy# Analysts5Avg. Consensus PT$13Upside to Avg. PT+87.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 11, 2026HC Wainwright & Co.Matthew CaufieldMaintainedBuy$12
Nov 14, 2025Cantor FitzgeraldJosh SchimmerInitiateOverweight$25
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on DiaMedica Therapeutics, Maintains $12 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and maintains $12 price target.
Benzinga Newsdesk

Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings

DiaMedica Therapeutics (NASDAQ: DMAC) will release Q4 earnings on March 30. Analysts expect a quarterly loss of 18 cents per share. Stock fell 0.9% on Friday.
Avi Kapoor

PRO
Cantor Fitzgerald Initiates Coverage On DiaMedica Therapeutics with Overweight Rating, Announces Price Target of $25

Cantor Fitzgerald analyst Josh Schimmer initiates coverage on DiaMedica Therapeutics (NASDAQ:DMAC) with a Overweight rating and announces Price Target of $25.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on DiaMedica Therapeutics, Maintains $12 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and maintains $12 price target.
Benzinga Newsdesk

PRO
Craig-Hallum Maintains Buy on DiaMedica Therapeutics, Raises Price Target to $11

Craig-Hallum analyst Chase Knickerbocker maintains DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and raises the price target from $8 to $11.
Benzinga Newsdesk

PRO
Lake Street Maintains Buy on DiaMedica Therapeutics, Raises Price Target to $14

Lake Street analyst Thomas Flaten maintains DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and raises the price target from $11 to $14.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved